GlassScriptPhysician profile
Michael P Marolda
NPI 1407206477
$4,516.21
in general payments reported to CMS, 2019-2025
29 companies · $1,566 in 2025
The $1,566 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $81.35 · 2023: $1,264 · 2024: $1,486 · 2025: $1,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,316.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $787.48 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $734.42 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $619.47 | 2022-2025 | |
| Novo Nordisk INC | $338.11 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $298.05 | 2023-2025 | |
| Lilly USA, LLC | $268.46 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Janssen Pharmaceuticals, INC | $222.49 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.40 | 2023-2025 | Jardiance, Ofev |
| Amgen INC. | $133.66 | 2023-2025 | Repatha, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $102.69 | 2023-2025 | Verquvo, Gardasil 9, Capvaxive |
| Viiv Healthcare Company | $98.13 | 2023-2025 | Apretude |
| Glaxosmithkline, LLC. | $88.65 | 2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Lundbeck LLC | $82.57 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $54.56 | 2024 | Veozah |
| Ardelyx, INC. | $51.01 | 2024 | Ibsrela |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $46.72 | 2024-2025 | |
| Inspire Medical Systems, INC. | $46.63 | 2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $45.20 | 2024 | Eliquis, Camzyos |
| Abbott Laboratories | $44.19 | 2021-2023 | Proclaim |
| Biogen, INC. | $43.26 | 2024-2025 | Zurzuvae |
| Regeneron Healthcare Solutions, INC. | $31.90 | 2024 | Evkeeza |
| Antares Pharma, INC. | $30.43 | 2025 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $29.02 | 2023 | Trintellix |
| Genzyme Corporation | $25.02 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.42 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $21.51 | 2025 | Voquezna |
| Neurocrine Biosciences, INC. | $16.21 | 2023 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $15.81 | 2024 | |
| Exact Sciences Corporation | $13.74 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Marolda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.